Mineralys (MLYS) Director Derek DiRocco Receives RSU Awards

What Happened

Derek DiRocco, a director of Mineralys Therapeutics, received equity awards on February 19, 2026. The filing reports two grant transactions (code A): 6,200 restricted stock units (RSUs) and 8,300 additional equity awards recorded as a derivative, for a total of 14,500 awards. Both grants were for $0.00 (no cash paid). These are awards/compensation grants rather than purchases or sales.

Key Details

• Transaction date: 2026-02-19; filing date: 2026-02-20 (timely).
• Reported amounts: 6,200 RSUs (grant) and 8,300 derivative awards — total 14,500.
• Reported price: $0.00 (awards granted for no cash consideration).
• Shares owned following the transaction: not specified in the provided filing details.
• Footnote highlights:
  • F1: RSUs are contingent rights to receive one share per RSU and vest in one annual installment following the grant.
  • F2: DiRocco holds these RSUs/options for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus III Fund, L.P.; he is obligated to turn over any cash/stock received to the Adviser to offset advisory fees and disclaims beneficial ownership.
  • F3: (If any options are involved) stock options referenced in the filing vest in 12 substantially equal monthly installments.
• Transaction code: A = Award/Grant.

Context

RSU grants are common compensation for directors and do not represent an outright market purchase or sale. Because these awards are held for the benefit of RA Capital funds and the reporting person disclaims beneficial ownership, this filing reflects institutional/fund-related holdings rather than a personal investment decision. Watch future filings for vesting/settlement events (when shares are issued or cash received), which may show ownership changes or related transactions.